Delcath Systems (NASDAQ:DCTH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Delcath Systems (NASDAQ:DCTH) from a hold rating to a buy rating in a research report released on Saturday.

A number of other analysts have also commented on DCTH. Stephens cut their price target on Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Delcath Systems in a report on Monday, December 29th. Canaccord Genuity Group reiterated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Tuesday, October 21st. BTIG Research restated a “buy” rating and issued a $23.00 price target on shares of Delcath Systems in a research report on Tuesday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Delcath Systems in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.40.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $10.29 on Friday. The firm’s fifty day moving average price is $9.62 and its two-hundred day moving average price is $10.59. The stock has a market cap of $363.34 million, a PE ratio of 1,029.00 and a beta of 0.39. Delcath Systems has a fifty-two week low of $8.12 and a fifty-two week high of $18.23.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. The company had revenue of $20.56 million during the quarter, compared to analysts’ expectations of $23.22 million. Delcath Systems had a return on equity of 7.02% and a net margin of 1.50%. As a group, sell-side analysts predict that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Delcath Systems declared that its Board of Directors has authorized a share repurchase program on Thursday, November 20th that permits the company to buyback $25.00 million in shares. This buyback authorization permits the company to buy up to 8.6% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Delcath Systems

In other Delcath Systems news, CEO Gerard J. Michel acquired 11,500 shares of the stock in a transaction dated Tuesday, November 11th. The stock was purchased at an average cost of $8.53 per share, with a total value of $98,095.00. Following the transaction, the chief executive officer owned 330,834 shares in the company, valued at approximately $2,822,014.02. The trade was a 3.60% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 17.94% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Delcath Systems

Several large investors have recently added to or reduced their stakes in DCTH. USA Financial Formulas bought a new stake in shares of Delcath Systems in the second quarter valued at approximately $25,000. California State Teachers Retirement System purchased a new stake in shares of Delcath Systems during the second quarter worth $26,000. Russell Investments Group Ltd. bought a new position in shares of Delcath Systems in the third quarter worth $29,000. Tower Research Capital LLC TRC purchased a new position in shares of Delcath Systems in the second quarter valued at $40,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in Delcath Systems during the 2nd quarter worth about $42,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.